Literature DB >> 14678336

Stroke, dementia, and drug delivery.

G A Ford1, C A Bryant, A A Mangoni, S H D Jackson.   

Abstract

Stroke and dementia represent a major health burden for elderly subjects as they are associated with significant morbidity and mortality. The rates of stroke and dementia are progressively increasing due to the ageing population in most westernized countries. Therefore, both these conditions represent a major therapeutic target. However, the therapeutic options available for the management of stroke and dementia remain largely unsatisfactory, the main reason being the difficulty in transferring the results obtained in animal and in vitro studies to the clinical setting. This review focuses on the recent advances in pathophysiology and treatment of these conditions and future directions for research. Moreover, the technique of functional magnetic resonance imaging is discussed in detail as a tool to assess the effects of therapeutic agents on the central nervous system and monitor the progression of diseases. Finally, an overview of the issue of drug delivery into the central nervous system is presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678336      PMCID: PMC1884409          DOI: 10.1046/j.1365-2125.2003.01939.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  98 in total

1.  The effect of normal aging on the coupling of neural activity to the bold hemodynamic response.

Authors:  M D'Esposito; E Zarahn; G K Aguirre; B Rypma
Journal:  Neuroimage       Date:  1999-07       Impact factor: 6.556

2.  Rapid ambulance protocol for acute stroke.

Authors:  J Harbison; A Massey; L Barnett; D Hodge; G A Ford
Journal:  Lancet       Date:  1999-06-05       Impact factor: 79.321

3.  Determination of drug-induced changes in functional MRI signal using a pharmacokinetic model.

Authors:  A S Bloom; R G Hoffmann; S A Fuller; J Pankiewicz; H H Harsch; E A Stein
Journal:  Hum Brain Mapp       Date:  1999       Impact factor: 5.038

Review 4.  The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease.

Authors:  R Cacabelos; M Takeda; B Winblad
Journal:  Int J Geriatr Psychiatry       Date:  1999-01       Impact factor: 3.485

5.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

6.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

Review 7.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

8.  Acute application of NGF increases the firing rate of aged rat basal forebrain neurons.

Authors:  D S Albeck; C Bäckman; L Veng; P Friden; G M Rose; A Granholm
Journal:  Eur J Neurosci       Date:  1999-07       Impact factor: 3.386

9.  Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

Authors:  B J O'Brien; R Goeree; M Hux; M Iskedjian; G Blackhouse; M Gagnon; S Gauthier
Journal:  J Am Geriatr Soc       Date:  1999-05       Impact factor: 5.562

10.  Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters.

Authors:  D F Emerich; P Snodgrass; R Dean; M Agostino; B Hasler; M Pink; H Xiong; B S Kim; R T Bartus
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

View more
  5 in total

Review 1.  Neuroprotection in experimental stroke with targeted neurotrophins.

Authors:  Dafang Wu
Journal:  NeuroRx       Date:  2005-01

2.  Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain.

Authors:  Mostafa Rahvar; Mohsen Nikseresht; Sayed Mohammad Shafiee; Fakhraddin Naghibalhossaini; Mozhgan Rasti; Mohammad Reza Panjehshahin; Ali Akbar Owji
Journal:  Neurochem Res       Date:  2011-01-09       Impact factor: 3.996

3.  Exact location of sensorimotor cortex injury after photochemical modulation; evidence of stroke based on stereological and morphometric studies in mice.

Authors:  Maryam Shahi; Ali Abedelahi; Daryoush Mohammadnejad; Reza Rahbarghazi; Seyed Hossein Rasta; Mohammad Karimipour
Journal:  Lasers Med Sci       Date:  2020-04-15       Impact factor: 3.161

4.  Microfluidic investigation of BDNF-enhanced neural stem cell chemotaxis in CXCL12 gradients.

Authors:  Hui Xu; Sarah C Heilshorn
Journal:  Small       Date:  2012-10-26       Impact factor: 13.281

5.  Combined ligand and structure-based virtual screening approaches for identification of novel AChE inhibitors.

Authors:  Kader Şahİn; Serdar DurdaĞi
Journal:  Turk J Chem       Date:  2020-06-01       Impact factor: 1.239

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.